<DOC>
	<DOCNO>NCT02176876</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics ( PK ) multiple infusion GS-5745 adult rheumatoid arthritis ( RA ) . Participants randomize 4:1 ratio receive 1 intravenous ( IV ) infusion GS-5745 placebo every 2 week , total 3 IV infusion .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics GS-5745 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>18 70 year age , inclusive , time screen Weight : ≥ 45 &lt; 120 kg Males nonpregnant , nonlactating female Diagnosis RA accord 1987 revised American College Rheumatology ( ACR ) classification RA Active disease , define mean high sensitivity Creactive protein ( hsCRP ) value Visits 1 &amp; 2 ≥ 8 mg/L Individuals take chronic DiseaseModifying Antirheumatic Drugs ( DMARDs ) stable dose least 45 day prior randomization Chronic use systemic corticosteroid maximum 10 mg/day prednisone equivalent allow dose stable least 30 day prior randomization Nonsteroidal Antiinflammatory Drugs ( NSAIDs ) analgesic allow dos stable least 30 day prior randomization Have document medical history anaphylaxis Positive HIV antibody screen Positive hepatitis B surface antigen ( HBsAg ) , positive hepatitis B core antigen ( HBcAg ) , follow positive hepatitis B virus ( HBV ) DNA quantitative polymerase chain reaction ( PCR ) screen Positive hepatitis C virus ( HCV ) antibody follow positive HCV viral RNA screen A positive QuantiFERONtuberculosis ( TB ) GOLD test screen History malignancy within last 5 year except individual treat locally nonmelanoma skin cancer cervical carcinoma situ Severe dementia Alzheimer 's disease , chronic medical psychiatric problem , alcohol drug abuse , judgment investigator may interfere individual 's ability comply study procedures Any serious cardiac event myocardial infarction , unstable lifethreatening arrhythmia , hospitalization cardiac failure within 6 month prior randomization significant new ECG find Visit 1 judge investigator History significant systemic involvement secondary RA vasculitis , pulmonary fibrosis , Felty 's syndrome History current inflammatory joint disease , RA , gout , reactive arthritis , psoriatic arthritis , seronegative spondylarthritis , Lyme disease History current autoimmune rheumatic disorder , RA , systemic lupus erythematosus , inflammatory bowel disease , fibromyalgia , polymyalgia rheumatic , scleroderma , inflammatory myopathy , mixed connective tissue disease , overlap syndrome Any chronic medical condition ( include , limited , cardiac pulmonary disease ) , judgment investigator , would make individual unsuitable study would prevent compliance study protocol Treatment antibiotic clinical infection medical condition within 30 day prior randomization Treatment azathioprine cyclosporine 90 day prior randomization Treatment infliximab , golimumab , adalimumab , abatacept , tocilizumab within 90 day ; etanercept anakinra within 30 day randomization Treatment rituximab Bcell deplete agent within 12 month randomization Treatment market investigational biologic within 5 halflives molecule unknown within 90 day randomization Administration investigational drug use investigational device within 30 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>GS-5745</keyword>
	<keyword>MMP9</keyword>
	<keyword>phase 1</keyword>
</DOC>